Interv Akut Kardiol. 2008;7(3):115-118

The role of echocardiography before and after catheter ablation for atrial fibrillation

Libor Škňouřil, Martin Fiala
Kardiocentrum Nemocnice Podlesí, Třinec

Catheter ablation has become a routine method in treatment of atrial fibrillation. Echocardigraphy represents an essential imaging method in cardiology, without which complex ablation procedures could not be performed safely. Obtaining information on structural condition of the heart, and ruling out the presence of an atrial thrombus are the primary aims of echocardiography prior to the ablation. During the ablation procedure, echocardiography remains the mainstay of exclusion of immediate and gradually evolving complications like bleeding into pericardium and pulmonary vein stenosis. There is an increasing role of echocardiography in assessment of morphology and function of the left atrium after ablation. Particularly, evaluation of the left atrial appendage flow velocity as an indicator of its preserved, respectively improved mechanical function after successful ablation appears to be a significant element of the decision, whether or not the lifelong anticoagulation therapy can be discontinued after ablation. Use of intracardiac echocardiography has been recently spreading out to help to navigate transseptal puncture, image anatomical structures, and to reveal early procedure-related complications.

Keywords: atrial fibrillation, catheter ablation, echocardiography

Published: December 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škňouřil L, Fiala M. The role of echocardiography before and after catheter ablation for atrial fibrillation. Interv Akut Kardiol. 2008;7(3):115-118.
Download citation

References

  1. Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978; 28: 973-977. Go to original source... Go to PubMed...
  2. Wolf PA, Abbot RD, Kannel WB, et al. Atrial fibrillation as independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-988. Go to original source... Go to PubMed...
  3. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158: 229-34. Go to original source... Go to PubMed...
  4. Benjamin EJ, Wolf PA, D´Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-52. Go to original source... Go to PubMed...
  5. Dries DL, Aarons D, Exner DV, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction. A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695-703. Go to original source... Go to PubMed...
  6. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigators of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104: 292-296. Go to original source... Go to PubMed...
  7. Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996; 131: 790-5. Go to original source... Go to PubMed...
  8. Furberg CD, Psaty BM, Manolio TA, et al. CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241. Go to original source... Go to PubMed...
  9. Manolio TA, Furberg CD, Rautaharju PM, et al. Cardiac arrhythmias on 24 hour ambulatory electrocardiography in older women and men: The Cardiovascular Health Study. J Am Coll Cardiol 1994; 23: 916-924. Go to original source... Go to PubMed...
  10. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82 (Suppl. 8A): 2N-9N. Go to original source... Go to PubMed...
  11. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93-100. Go to original source... Go to PubMed...
  12. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence. Circulation 2006; 114: 119-125. Go to original source... Go to PubMed...
  13. Roy D, Takajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920. Go to original source... Go to PubMed...
  14. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl. J Med 2005; 352: 1861-1872. Go to original source... Go to PubMed...
  15. The Atrial Fibrillation Follow up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. Go to original source... Go to PubMed...
  16. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179. Go to original source... Go to PubMed...
  17. The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
  18. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. Final results. Circulation 1991; 84: 527-539. Go to original source... Go to PubMed...
  19. Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-539.
  20. Ezekowitz M, Bridgers S, James K, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327; 1406-1412. Go to original source... Go to PubMed...
  21. Fiala M, Chovančík J, Heinc P, et al. Léčba symptomatické intermitentní fibrilace síní katetrovou ablací v levé srdeční síni. Bezprostřední a dlouhodobé výsledky u 150 pacientů. Vnitř Lék 2005; 51: 971-983.
  22. Fiala M, Chovančík J, Nevřalová R, et al. Pulmonary vein isolation using segmental versus electroanatomical circumferential ablation for paroxysmal atrial fibrillation: over 3-year results of a prospective randomized study. J Interv Cardiovasc Electrophysiol 2008; v tisku. Go to original source...
  23. Fiala M, Chovančík J, Neuwirth R, Nevřalová R, Jiravský O, Szymeczek H, Wojnarová D, Moravec R, Šknouřil L, Dorda M, Januška J, Nykl I, Černý J, Branny M. Katetrová ablace pro chronickou fibrilaci síní metodou obkružujících a komplexních lineárních lézí v levé srdeční síni: ukončení arytmie při ablaci a dlouhodobé klinické výsledky. Vnitř Lék. 2007; 53: 231-241. Go to PubMed...
  24. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. The APAF study. J Am Coll Cardiol 2006; 48: 2340-2347. Go to original source... Go to PubMed...
  25. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221. Go to original source... Go to PubMed...
  26. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-2640. Go to original source... Go to PubMed...
  27. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42: 185-197. Go to original source... Go to PubMed...
  28. Oral H, Chugh A, Özaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114: 759-765. Go to original source... Go to PubMed...
  29. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37: 691-704. Go to original source... Go to PubMed...
  30. Task Force members, Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary: The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2004; 25: 587-610. Go to original source... Go to PubMed...
  31. Dorda M, Fiala M, Januška J, et al. M. Úloha jícnové echokardiografie v hodnocení morfologických i funkčních parametrů plicních žil se zaměřením na detekci stenózy plicní žíly po radiofrekvenční ablaci pro fibrilaci síní. Cor Vasa 2006; 48: 19-23. Go to original source...
  32. Lonnerholm Sm Blomstrom P, Nilsson L, et al. Atrial size and transport function after the MAZE III procedure for paroxysmal atrial fibrillation. Ann Thorac Surg 2002; 73107-111. Go to original source... Go to PubMed...
  33. Verma A, Kilicalsan F, Adams JR, et al. Extensive ablation dutiny pulmonary vein antrum isolation has no averse impact on left atrial function: an echocardiography and cine computed tomography analysis. J Cardiovasc Electrophysiol 2006; 17: 741-746. Go to original source... Go to PubMed...
  34. Abhayaratna WP, Seward JB, Appleton CP, et al. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 2006; 47: 2357-2363. Go to original source... Go to PubMed...
  35. Lewis JF, Kuo LC, Nelson JG, et al. Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: Clinical validation of two new methods using the apical window. Circulation 1984; 70: 425-431. Go to original source... Go to PubMed...
  36. Shin SH, Park MY, Oh WJ, et al. Left atrial volume is a predictor of atrial fibrillation recurrence after catheter ablation. J Am Soc Echocardiogr 2008; (Epub ahead of print). Go to original source... Go to PubMed...
  37. Jue J, Winslow T, Nikutta P, et al. Pulsed Doppler characterization of left atrial appendage flow. J Am Soc Echocardiogr 1993; 6: 237-244. Go to original source... Go to PubMed...
  38. Antonielli E, Pizzuti A, Palinkas A, Tanga M, et al. Clinical Value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2002; 39: 1443-1449. Go to original source... Go to PubMed...
  39. Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation/SPAFF-III/study). J Am Soc Echocardiogr 1999; 12: 1080-1087. Go to original source... Go to PubMed...
  40. Kamalesh M, Copeland TB, Sawada S. Severely reduced left atrial appendage function: a cause of embolic stroke in patients in sinus rythm? J Am Soc Echokardiogr 1998; 11: 902-904. Go to original source... Go to PubMed...
  41. Uslu N, Nurkalem Z, Orhan AL, et al. Transthoracic echocardiographic predictors of the left atrial appendage contraction velocity in stroke patients with sinus rhythm. Tohoku J Exp Med 2006; 208: 291-298. Go to original source... Go to PubMed...
  42. Beukema WP, Elvan A, Sie HT, et al. Successful radiofrequency ablation in patients with previous atrial fibrillation results in a significant decrease in left atrial size. Circulation 2005; 112: 2089-2095. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.